✦ LIBER ✦

Changes in different regions of hepatitis B virus gene in hepatitis B ‘e’ antigen-negative patients with chronic hepatitis B: the effect of long-term lamivudine therapy

✍ Scribed by M. Buti; R. Jardi; F. Rodriguez-Frias; A. Valdes; M. Schaper; R. Esteban; J. Guardia

Book ID: 108604114
Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 79 KB
Volume: 21
Category: Article
ISSN: 0269-2813
DOI: 10.1111/j.1365-2036.2005.02503.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy of lamivudine in patients with

Efficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis befficacy of lamivudine in patients with hepatitis B e antigen–negative/hepatitis B virus DNA–positive (precore mutant) chronic hepatitis BB

✍ Nicolaos C. Tassopoulos; Riccardo Volpes; Giuseppe Pastore; Jenny Heathcote; Mar 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 152 KB 👁 1 views

This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ‫؍‬ 60

Long-term follow-up of patients with hep

Long-term follow-up of patients with hepatitis B e antigen negative chronic hepatitis B

✍ Dan Bekku; Makoto Arai; Fumio Imazeki; Yutaka Yonemitsu; Tatsuo Kanda; Keiichi F 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB

Adefovir dipivoxil added to ongoing lami

Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B

✍ T. Vassiliadis; N. Nikolaidis; O. Giouleme; K. Tziomalos; N. Grammatikos; K. Pat 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Outcome of hepatitis B e antigen–negativ

Outcome of hepatitis B e antigen–negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine

✍ George V. Papatheodoridis; Evangelini Dimou; Konstantinos Dimakopoulos; Spilios 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 1 views

We determined the clinical outcome of hepatitis e antigen (HBeAg)-negative chronic hepatitis B patients treated with long-term nucleos(t)ide analog therapy starting with lamivudine. We evaluated 201 such patients treated for 3.8 ؎ 1.4 years and 2 historical similar cohorts: 1 treated with interferon

Long-term therapy with adefovir dipivoxi

Long-term therapy with adefovir dipivoxil in hepatitis B e antigen-negative patients developing resistance to lamivudine

✍ S. MANOLAKOPOULOS; S. BETHANIS; S. KOUTSOUNAS; J. GOULIS; J. VLACHOGIANNAKOS; E. 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

Low frequency of precore hepatitis B vir

Low frequency of precore hepatitis B virus mutants in anti-hepatitis B e—positive reactivation after loss of hepatitis B e antigen in patients with chronic hepatitis B

✍ Marie Anne Loriot; Patrick Marcellin; Nathalie Talbodec; Véronique Guigonis; Mic 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 611 KB

The objective of this study was to evaluate the role of hepatitis B virus (HBV) precore mutations in patients with anti-me-positive chronic hepatitis B with or without previous known HBe antigen (HBeAg) viremic phase, and to assess the potential implication of precore mutants in HBeAg-negative react